Whereas the respiratory system has been the primary focus in the past decades, as 90% of people with CF (pwCF) died prematurely from pulmonary destruction, the recent improvement in the course of the disease, including highly effective CFTR-modulating therapies (HEMT) availability, has brought the multi-organ abdominal involvement into clinical and scientific focus [3]. This evidence concerns the gene CFTR and cystic fibrosis.